-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 TyNODreOBdEWcLv5VTuxsJablLGK9KTWRv83bnfdlEGmckIKmHeK1cJ/DicwrCdq
 E1jZI/tecxY6HueOUl33vw==

<SEC-DOCUMENT>0001297077-08-000031.txt : 20080402
<SEC-HEADER>0001297077-08-000031.hdr.sgml : 20080402
<ACCEPTANCE-DATETIME>20080402125334
ACCESSION NUMBER:		0001297077-08-000031
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20071022
ITEM INFORMATION:		Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20080402
DATE AS OF CHANGE:		20080402

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CHAMPIONS BIOTECHNOLOGY, INC.
		CENTRAL INDEX KEY:			0000771856
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				521401755
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0430

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-17263
		FILM NUMBER:		08732267

	BUSINESS ADDRESS:	
		STREET 1:		2200 WILSON BLVD
		STREET 2:		SUITE 102-316
		CITY:			ARLINGTON
		STATE:			VA
		ZIP:			22201
		BUSINESS PHONE:		703-526-0400

	MAIL ADDRESS:	
		STREET 1:		2200 WILSON BLVD.
		STREET 2:		SUITE 102-316
		CITY:			ARLINGTON
		STATE:			VA
		ZIP:			22201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHAMPIONS SPORTS INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERNATIONAL GROUP INC
		DATE OF NAME CHANGE:	19860319
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>cbi8k_04022008.htm
<TEXT>
<html>
<head><meta content="text/html; charset=">
<title>UNITED STATES</title>
</head>

<body >
<ul>
</ul>

<div style="position:relative; left: -5"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="733.333150" colspan="1" rowspan="1" >
<p align="center">
<font size="2"><b>UNITED STATES</b></font></p align="center">
</td>
</tr>
<tr valign="top">
<td width="733.333150" colspan="1" rowspan="1" >
<p align="center">
<font size="2"><b>SECURITIES AND EXCHANGE COMMISSION</b></font></p align="center">
</td>
</tr>
<tr valign="top">
<td width="733.333150" colspan="1" rowspan="1" >
<p align="center">
<font size="2"><b>Washington, D.C. 20549</b></font></p align="center">
</td>
</tr>
<tr valign="top">
<td width="733.333150" colspan="1" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="733.333150" colspan="1" rowspan="1" >
<p align="center">
<font size="2"><b>FORM 8-K</b></font></p align="center">
</td>
</tr>
<tr valign="top">
<td width="733.333150" colspan="1" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="733.333150" colspan="1" rowspan="1" >
<p align="center">
<font size="2"><b>CURRENT REPORT</b></font></p align="center">
</td>
</tr>
<tr valign="top">
<td width="733.333150" colspan="1" rowspan="1" >
<p align="center">
<font size="2">Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934</font></p align="center">
</td>
</tr>
<tr valign="top">
<td width="733.333150" colspan="1" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="733.333150" colspan="1" rowspan="1" >
<p align="center">
<font size="2">Date of Report (Date of earliest event reported)</font></p align="center">
</td>
</tr>
<tr valign="top">
<td width="733.333150" colspan="1" rowspan="1" >
<p align="center">
<font size="2">March 31, 2008</font></p align="center">
</td>
</tr>
<tr valign="top">
<td width="733.333150" colspan="1" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="733.333150" colspan="1" rowspan="1" >
<p align="center">
<font size="2">CHAMPIONS BIOTECHNOLOGY, INC.</font></p align="center">
</td>
</tr>
<tr valign="top">
<td width="733.333150" colspan="1" rowspan="1" >
<p align="center">
<font size="2">(Exact name of registrant as specified in its charter)</font></p align="center">
</td>
</tr>
</table></div>
<p>
</p align="center">
<div style="position:relative; left: -5"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="227.999943" colspan="1" rowspan="1" >
<p align="center">
<font size="2">Delaware</font></p align="center">
</td>
<td width="269.333266" colspan="1" rowspan="1" >
<p align="center">
<font size="2">0-17263</font></p align="center">
</td>
<td width="234.666608" colspan="1" rowspan="1" >
<p align="center">
<font size="2">52-1401755</font></p align="center">
</td>
</tr>
<tr valign="top">
<td width="227.999943" colspan="1" rowspan="1" >
<p align="center">
<font size="2">(State of other jurisdiction</font></p align="center">
</td>
<td width="269.333266" colspan="1" rowspan="1" >
<p align="center">
<font size="2">(Commission</font></p align="center">
</td>
<td width="234.666608" colspan="1" rowspan="1" >
<p align="center">
<font size="2">(IRS Employer</font></p align="center">
</td>
</tr>
<tr valign="top">
<td width="227.999943" colspan="1" rowspan="1" >
<p align="center">
<font size="2">of incorporation)</font></p align="center">
</td>
<td width="269.333266" colspan="1" rowspan="1" >
<p align="center">
<font size="2">File Number)</font></p align="center">
</td>
<td width="234.666608" colspan="1" rowspan="1" >
<p align="center">
<font size="2">Identification No.)</font></p align="center">
</td>
</tr>
</table></div>
<p>
</p align="center">
<div style="position:relative; left: -5"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="503.999874" colspan="1" rowspan="1" >
<p align="center">
<font size="2">1400 North 14<sup>th</sup> Street</font></p align="center">
</td>
<td width="227.999943" colspan="1" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="503.999874" colspan="1" rowspan="1" >
<p align="center">
<font size="2">Arlington, VA</font></p align="center">
</td>
<td width="227.999943" colspan="1" rowspan="1" >
<p>
<font size="2">22209</font></p>
</td>
</tr>
<tr valign="top">
<td width="503.999874" colspan="1" rowspan="1" >
<p align="center">
<font size="2">(Address of principal executive offices)</font></p align="center">
</td>
<td width="227.999943" colspan="1" rowspan="1" >
<p>
<font size="2">(Zip Code)</font></p>
</td>
</tr>
</table></div>
<p>
</p align="center">
<div style="position:relative; left: -5"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="733.333150" colspan="1" rowspan="1" >
<p align="center">
<font size="2">Registrant&#8217;s telephone number, including area code: (410) 630-1313</font></p align="center">
</td>
</tr>
<tr valign="top">
<td width="733.333150" colspan="1" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="733.333150" colspan="1" rowspan="1" >
<p align="center">
<font size="2">(Former name or former address, if changed since last report.)</font></p align="center">
</td>
</tr>
<tr valign="top">
<td width="733.333150" colspan="1" rowspan="1" >
<p align="center">
<font size="2">2200 Wilson Blvd., Suite 102-316, Arlington, VA 22201</font></p align="center">
</td>
</tr>
</table></div>
<p>
<br><font size="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant </font><br><font size="2">under any of the following provisions (see General Instruction A.2. below):</font><br></p>
<div style="position:relative; left: -5"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="733.333150" colspan="1" rowspan="1" >
<p>
<font size="2">[&nbsp;&nbsp;] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></p>
</td>
</tr>
<tr valign="top">
<td width="733.333150" colspan="1" rowspan="1" >
<p>
<font size="2">[&nbsp;&nbsp;] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></p>
</td>
</tr>
<tr valign="top">
<td width="733.333150" colspan="1" rowspan="1" >
<p>
<font size="2">[&nbsp;&nbsp;] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></p>
</td>
</tr>
<tr valign="top">
<td width="733.333150" colspan="1" rowspan="1" >
<p>
<font size="2">[&nbsp;&nbsp;] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></p>
</td>
</tr>
</table></div>
<p>
</p align="right">
<div style="position:relative; left: -5"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="733.333150" colspan="1" rowspan="1" >
<p align="right" style="border-bottom:double">
<font size="2" color="#000080">1</font></p>
</td>
</tr>
</table></div>
<p>
<a name="part_1_2_1"></a><a name="item_1_41_1"></a><font size="2"><b>Item 5.02 &nbsp;&nbsp;Departure of Directors or Principal Officers; Election of Directors; Appointment of Certain Officers; Compensatory </b></font><br><font size="2"><b>Arrangements of Certain Officers</b></font><br><br><font size="2">NEW DIRECTORS</font><br><br><font size="2">Champions Biotechnology, Inc., (the &#8220;Company&#8221;) announced that effective March 31, 2008, Manuel Hidalgo M.D., Ph.D., </font><br><font size="2">Durwood Settles and Michael Tomic resigned as directors of the Company. No disagreements with the Company were cited by </font><br><font size="2">any director in connection with their respective resignations.  </font><br><br><font size="2">At the same time, Abba David Poliakoff and Ana I. Stancic were appointed as independent directors. Information regarding each </font><br><font size="2">new director is presented in the text of the attached related press release (Exhibit 99.1)</font><br><br><font size="2">The Board
 adopted a Director Compensation Plan whereby each new Director receives an initial grant of stock options to </font><br><font size="2">purchase 50,000 shares of common stock, vesting over a three year period, and options to purchase 20,000 shares each additional </font><br><font size="2">year.  The exercise price is the market price of the common stock on the date of grant.  The Chairman of the Board will receive </font><br><font size="2">an annual grant of 40,000 shares.</font><br><br><font size="2">NEW OFFICERS</font><br><br><font size="2">In addition, effective March 31, 2008 Douglas D. Burkett, Ph.D. was appointed to serve as the Company&#8217;s President, and Manuel </font><br><font size="2">Hidalgo M.D., Ph.D., stepped off the Board to serve in a consulting role as the Company&#8217;s Chief Scientific Officer.  Durwood </font><br><font size="2">Settles was appointed as the acting Chief Financial Officer.  James M. Martell, the Company&#8217;s founder and director who also </font><br><font size="2">ser
ved as President and CEO as well as CFO, resigned those positions effective March 31, 2008 and was appointed Chief </font><br><font size="2">Administrative Officer.  Information regarding each new officer is presented in the text of the attached related press release </font><br><font size="2">(Exhibit 99.1)</font><br><br><font size="2">EMPLOYMENT AGREEMENTS</font><br><br><a name="OLE_LINK1"></a><a name="OLE_LINK2"></a><font size="2">The Company entered into an employment agreement dated March 27, 2008 with Dr. Burkett to serve as President.  The term of </font><br><font size="2">the agreement commences on March 31, 2008 and extends for a two-year period, renewing automatically for successive one year </font><br><font size="2">periods unless notice of non-renewal is given.  Dr. Burkett&#8217;s compensation includes a salary of $225,000 per annum, participation </font><br><font size="2">in Company employee benefit plans and reconfirmation of an option previously granted on October 10, 2007 to acquire 500,000 <
/font><br><font size="2">shares of common stock at an exercise price of $0.75 per share, the market price of the common stock on the date the option was </font><br><font size="2">issued.  The options to purchase shares vest at the rate of 166,665 shares on the first anniversary of the grant date, 166,665 shares </font><br><font size="2">on the second anniversary of the grant date and 166,670 shares on the third anniversary of the grant date.  All vested options will </font><br><font size="2">be exercisable over a five-year period expiring on the fifth anniversary of the grant date, provided that the options will terminate </font><br><font size="2">upon a material breach by the executive of the employment agreement.  The agreement further provides that if the Company </font><br><font size="2">terminates the executive&#8217;s employment without cause, the Company shall pay the executive severance equal to four months&#8217; </font><br><font size="2">salary and his options shall immediately vest.</font><br><br>
<font size="2">The Company entered into an employment agreement dated March 31, 2008 with James Martell to serve as Chief Administrative </font><br><font size="2">Officer.  The term of the agreement commences on March 31, 2008 and extends for a one-year period, renewing automatically </font><br><font size="2">for successive one year periods unless notice of non-renewal is given.  Mr. Martell&#8217;s compensation includes a salary of $185,000 </font><br><font size="2">per annum and participation in Company employee benefit plans.  The agreement further provides that if the Company terminates </font><br><font size="2">the executive&#8217;s employment without cause, the Company shall pay the executive severance equal to three months&#8217; salary.</font><br><font size="2">The text of the related press release, which is attached as Exhibit&nbsp;99.1, is incorporated by reference herein in its entirety.</font><br><br><a name="part_1_2_2"></a><a name="item_1_47_1"></a><font size="2"><b>Item 9.01.&nbsp;&nbsp;Financ
ial Statements and Exhibits</b></font><br></p>
<div style="position:relative; left: 33"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="37.333324" colspan="1" rowspan="1" >
<p>
<font size="2">(d)</font></p>
</td>
<td width="635.999841" colspan="1" rowspan="1" >
<p>
<font size="2">Exhibits</font></p>
</td>
</tr>
<tr valign="top">
<td width="37.333324" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="635.999841" colspan="1" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="37.333324" colspan="1" rowspan="1" >
<p>
<font size="2">99.1&nbsp;</font></p>
</td>
<td width="635.999841" colspan="1" rowspan="1" >
<p>
<font size="2">Press release April 1, 2008</font></p>
</td>
</tr>
</table></div>
<p>
</p align="center">
<div style="position:relative; left: -5"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="733.333150" colspan="1" rowspan="1" >
<p align="center">
<a name="part_1_2_3"></a><font size="2"><b>SIGNATURES</b></font></p align="center">
</td>
</tr>
</table></div>
<p>
<br><font size="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the </font><br><font size="2">undersigned thereunto duly authorized.</font><br></p>
<div style="position:relative; left: 0"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="287.999928" colspan="1" rowspan="1" >
<p>
<font size="2">Date: April 1, 2008</font></p>
</td>
<td width="261.333268" colspan="2" rowspan="1" >
<p>
<font size="2">CHAMPIONS BIOTECHNOLOGY, INC.</font></p>
</td>
</tr>
<tr valign="top">
<td width="550.666529" colspan="3" rowspan="1" >
<p>
<font size="2">&nbsp;</font></p>
</td>
</tr>
<tr valign="top">
<td width="287.999928" colspan="1" rowspan="1" >
<p>
<font size="2">&nbsp;</font></p>
</td>
<td width="50.666654" colspan="1" rowspan="1" >
<p>
<font size="2">By:</font></p>
</td>
<td width="210.666614" colspan="1" rowspan="1" >
<p>
<font size="2"><u>/s/&nbsp;&nbsp;Douglas D. Burkett</u></font></p>
</td>
</tr>
<tr valign="top">
<td width="287.999928" colspan="1" rowspan="1" >
<p>
<font size="2">&nbsp;</font></p>
</td>
<td width="50.666654" colspan="1" rowspan="1" >
<p>
<font size="2">&nbsp;&nbsp;</font></p>
</td>
<td width="210.666614" colspan="1" rowspan="1" >
<p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Douglas D. Burkett</font></p>
</td>
</tr>
<tr valign="top">
<td width="287.999928" colspan="1" rowspan="1" >
<p>
<font size="2">&nbsp;</font></p>
</td>
<td width="50.666654" colspan="1" rowspan="1" >
<p>
<font size="2">&nbsp;&nbsp;</font></p>
</td>
<td width="210.666614" colspan="1" rowspan="1" >
<p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;President</font></p>
</td>
</tr>
</table></div>
<p>
</p align="right">
<div style="position:relative; left: -5"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="733.333150" colspan="1" rowspan="1" >
<p align="right" style="border-bottom:double">
<a name="doc_1_2"></a><font size="2" color="#000080">2</font></p>
</td>
</tr>
</table></div>
<p>
</p>


</body>

</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>cbi8k_04012008-pressrel.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
<head><meta content="text/html; charset=">
<title> </title>
</head>

<body >
<ul>
</ul>

<p>
<font face="Arial" size="2"><img height="72" width="225" src="cbi8k_04012008-pressrel00.jpg" 	alt="cbi8k_04012008-pressrel00.jpg" border="0" ></font><br></p align="right">
<div style="position:relative; left: -5"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
<p align="right" style="border-bottom:solid windowtext .5pt">
<font face="Arial" size="4"><b>NEWS</b></font></p>
</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
<p align="center">
<font face="Arial" size="2">1400 North 14<sup>th</sup> Street, Arlington, Virginia 22209 USA. Tel. 410-630-1313</font></p align="center">
</td>
</tr>
</table></div>
<p>
<br><font face="Arial" size="2">For Immediate Release</font><br></p align="center">
<div style="position:relative; left: -5"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
<p align="center">
<font face="Arial" size="2"><b>Champions Biotechnology, Inc. Appoints New Board Members and</b></font></p align="center">
</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
<p align="center">
<font face="Arial" size="2"><b>Forms Management Team</b></font></p align="center">
</td>
</tr>
</table></div>
<p>
<br><font face="Arial" size="2">Arlington, VA, April 1, 2008. Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the </font><br><font face="Arial" size="2">development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, </font><br><font face="Arial" size="2">announced today the appointment of new Board of Directors members and the formation of an experienced </font><br><font face="Arial" size="2">management team as it prepares to expand its operations.    </font><br><br><font face="Arial" size="2">Abba David Poliakoff and Ana Stancic were appointed as new independent directors to the Company&#8217;s Board, </font><br><font face="Arial" size="2">chaired by Dr. David Sidransky.  The Board of Directors also established an Audit, Nominations and Corporate </font><br><font face="Arial" size="2">Governance and Compensation Committee.  The Company anticipates naming additional independent Board </font><br><font face="Arial" size="2">members i
n the future to properly constitute these committees as part of its growth initiatives and in furtherance of its </font><br><font face="Arial" size="2">plans to implement a state of the art corporate governance regime.</font><br><br><font face="Arial" size="2">The Company also formed a new management team. Douglas D. Burkett, Ph.D. has been appointed to serve as the </font><br><font face="Arial" size="2">Company&#8217;s President, Manuel Hidalgo M.D., Ph.D., has been named to serve as the Chief Scientific Officer and </font><br><font face="Arial" size="2">Durwood Settles will serve as the acting Chief Financial Officer.  James M. Martell, the Company&#8217;s founder and </font><br><font face="Arial" size="2">director, has been appointed Chief Administrative Officer and has relinquished the positions of CEO, President and </font><br><font face="Arial" size="2">CFO.</font><br><br><font face="Arial" size="2">&#8220;We are very pleased to have these outstanding individuals join our Board and management team as w
e grow our </font><br><font face="Arial" size="2">preclinical platform and the opportunities that we believe it will create,&#8221; stated Dr. David Sidransky, Chairman of the </font><br><font face="Arial" size="2">Board of Champions Biotechnology, Inc.  &#8220;We are grateful to Dr. Manuel Hidalgo, who has stepped off the Board as a </font><br><font face="Arial" size="2">director in order to head up our scientific efforts as Chief Scientific Officer, and thank past Board members, Durwood </font><br><font face="Arial" size="2">Settles and Michael Tomic for their dedicated Board service to the Company.  I also look forward to working closely </font><br><font face="Arial" size="2">with Dr. Doug Burkett as he leads management to achieve our goal to become the world leader in preclinical </font><br><font face="Arial" size="2">platforms and tumor specific data.&#8221; concluded Dr. Sidransky. </font><br><br><font face="Arial" size="2">Douglas D Burkett, Ph.D. commented, &#8220;I have collaborated and worked with 
Dr. David Sidransky for nearly a decade </font><br><font face="Arial" size="2">and I&#8217;m excited about the opportunity to help implement his vision for Champions to become one of the world&#8217;s </font><br><font face="Arial" size="2">leading biotech companies.  Please review the Company&#8217;s new web site at </font><font face="Arial" size="2" color="#0000ff"><u>www.championsbiotechnology.com</u></font><font face="Arial" size="2"> for an </font><br><font face="Arial" size="2">overview of our growing business.&#8221;</font><br><br><font face="Arial" size="2"><b>New Board Members:</b></font><br><br><font face="Arial" size="2"><b>Abba David Poliakoff</b> is a member of the law firm of Gordon, Feinblatt, Rothman, Hoffberger &amp; Hollander, LLC, in </font><br><font face="Arial" size="2">Baltimore, Maryland, Chairman of the Firm&#8217;s Business Department, and a Member of the Firm&#8217;s Electronic Discovery </font><br><font face="Arial" size="2">Practice Group.  Mr. Poliakoff received his J.D. degree, <
i>magna cum laude</i>, in 1977 from the University of Baltimore </font><br><font face="Arial" size="2">Law School, where he was an editor of the University of Baltimore Law Review and Associate Editor of The Forum </font><br><font face="Arial" size="2">Law Journal.  After law school, Mr. Poliakoff joined the staff of the U.S. Securities and Exchange Commission in </font><br><font face="Arial" size="2">Washington, D.C., where he became a senior attorney in the Division of Corporation Finance.  Mr. Poliakoff is </font><br><font face="Arial" size="2">currently a member of the Maryland State Bar Association&#8217;s Business Law Section and former Chair of its Committee </font><br><font face="Arial" size="2">on Securities.  Formerly he was a member of the Business Regulations Article Review Committee of the Committee </font><br></p align="right">
<div style="position:relative; left: -5"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
<p align="right" style="border-bottom:double">
<font size="2" color="#000080">1</font></p>
</td>
</tr>
</table></div>
<p>
<br><br><font face="Arial" size="2">to Revise the Maryland Annotated Code.  He has been listed in Chambers USA, Leading Business Lawyers since its </font><br><font face="Arial" size="2">inception in 2003.  Mr. Poliakoff is a member of the Board of Directors of the Greater Baltimore Technology Council </font><br><font face="Arial" size="2">(GBTC) and Chair of its Legislative Committee.  He is a former Chair of the Maryland Business &amp; Technology </font><br><font face="Arial" size="2">Coalition, member of the Technology Council of Maryland, and member of the MIT Enterprise Forum.  Mr. Poliakoff is </font><br><font face="Arial" size="2">currently the Chairman of the Maryland Israel Development Center, a joint venture between the State of Israel and </font><br><font face="Arial" size="2">the State of Maryland collaborating through the Maryland Department of Business and Economic Development and </font><br><font face="Arial" size="2">the Israeli Ministry of Industry and Trade.</font><br><br><font face="Arial" 
size="2"><b>Ana I. Stancic</b> has served since March, 2008 as Chief Financial Officer of Aureon Laboratories Incorporated </font><br><font face="Arial" size="2">("Aureon"), an oncology diagnostic company dedicated to enabling the advancement of predictive and personalized </font><br><font face="Arial" size="2">cancer treatment by performing diagnostic reference laboratory and clinical research services.  Prior to joining </font><br><font face="Arial" size="2">Aureon, Ms. Stancic was Executive Vice President and Chief Financial Officer at OMRIX Biopharmaceuticals, Inc.  </font><br><font face="Arial" size="2">Before joining OMRIX, Ms. Stancic served as Senior Vice President, Finance at ImClone Systems, Inc. (&#8220;ImClone&#8221;), a </font><br><font face="Arial" size="2">global biopharmaceutical company committed to advancing oncology care, where she was responsible for ImClone&#8217;s </font><br><font face="Arial" size="2">finance department, information technology and internal audit.  Ms. Stancic joined Im
Clone as Vice President, </font><br><font face="Arial" size="2">Controller and Chief Accounting Officer in 2004.  Prior to joining ImClone, she was Vice President and Controller at </font><br><font face="Arial" size="2">Savient Pharmaceuticals, Inc. from 2003 to February, 2004.  Ms. Stancic was Vice President and Chief Accounting </font><br><font face="Arial" size="2">Officer at Ogden Corporation from 1999 to 2002 and Regional Chief Financial Officer at OmniCare, Inc. from 1997 to </font><br><font face="Arial" size="2">1999.  Ms. Stancic began her career in 1985 at PricewaterhouseCoopers in the Assurance practice where she had </font><br><font face="Arial" size="2">responsibility for international and national companies in the pharmaceutical and services industries.  Ms. Stancic is a </font><br><font face="Arial" size="2">Certified Public Accountant and holds an M.B.A. degree from Columbia Business School. </font><br><br><font face="Arial" size="2"><b>New Management Team:  </b></font><br><br><font face="Aria
l" size="2"><b>President:</b>  <b>Douglas D. Burkett, Ph.D.</b> served as executive consultant to assist the Company in establishing and </font><br><font face="Arial" size="2">executing its strategic and business plan prior to becoming President.  Dr. Burkett served as Chairman, Chief </font><br><font face="Arial" size="2">Executive Officer and President of Zila, Inc. from 2002 to 2007 and led a strategic transformation of Zila into a cancer </font><br><font face="Arial" size="2">detection company.  He led the FDA approval, launch and growth of ViziLite Plus, an oral cancer screening product, </font><br><font face="Arial" size="2">and the establishment of the first insurance reimbursement for oral cancer screening products in the United States.  </font><br><font face="Arial" size="2">Dr. Burkett held several senior positions at Zila from 1995 to 2002; he was responsible for Zila&#8217;s technical operations, </font><br><font face="Arial" size="2">its manufacturing subsidiary, its Pharmaceuticals business and
 business development.  Early in his career he led the </font><br><font face="Arial" size="2">building of a R&amp;D laboratory, pharmaceutical manufacturing facility, compliance unit and regulatory team that </font><br><font face="Arial" size="2">achieved a rare &#8220;no deficiency&#8221; FDA pre approval inspection.  Dr. Burkett is the lead inventor in numerous issued and </font><br><font face="Arial" size="2">pending patents involving novel methods and drugs for cancer detection.  He is quoted in leading publications </font><br><font face="Arial" size="2">including the Wall Street Journal regarding his pioneering efforts in early oral cancer detection.  Prior to joining Zila, </font><br><font face="Arial" size="2">Dr. Burkett was employed at the Arizona State University Cancer Research Institute where he collaborated with the </font><br><font face="Arial" size="2">National Cancer Institute in synthesizing and performing studies for potential cancer treatment drugs.  Prior to his </font><br><font face="Ari
al" size="2">tenure at ASU he researched, developed and manufactured pharmaceutical drugs for a private pharmaceutical </font><br><font face="Arial" size="2">company.  Dr. Burkett received a B.S. in Chemistry from Missouri Western State College in 1987, and a Ph.D. in </font><br><font face="Arial" size="2">Organic Chemistry from Arizona State University in 1994.  </font><br><br><font face="Arial" size="2"><b>Chief Scientific Officer: Manuel Hidalgo, M.D., Ph.D.</b> served as Director and as Scientific Advisor since June, </font><br><font face="Arial" size="2">2007.  Dr. Hidalgo, for the past five years has been an Associate Professor of Oncology at the Sidney Kimmel </font><br><font face="Arial" size="2">Comprehensive Cancer Center, Johns Hopkins University School of Medicine.  He is also currently the Director of the </font><br><font face="Arial" size="2">Centro Integral Oncologia "Clara Campal" in Madrid, Spain.  Dr. Hidalgo is serving on the Scientific Advisory Boards </font><br><font face="Arial" size="2
">of private and public companies, including Systems Medicine, Tau Therapeutics, Targeted Molecular Diagnostics and </font><br><font face="Arial" size="2">Monogram Biosciences.  Dr. Hidalgo is considered a leading researcher in the field of targeted therapies for the </font><br><font face="Arial" size="2">treatment of cancer in patients with solid tumors.  Dr. Hidalgo has published over 140 papers in prestigious cancer </font><br><font face="Arial" size="2">journals as well as numerous chapters in important text books.  He has received numerous awards including an </font><br></p align="right">
<div style="position:relative; left: -5"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
<p align="right" style="border-bottom:double">
<font size="2" color="#000080">2</font></p>
</td>
</tr>
</table></div>
<p>
<br><br><font face="Arial" size="2">AACR Young Investigator Award, an NCI-EORTC fellowship and an ASCO Career Development Award.  He has </font><br><font face="Arial" size="2">served on the editorial board of the Journal of Clinical Oncology and Clinical Cancer Research and is a Senior Editor </font><br><font face="Arial" size="2">for Molecular Cancer Therapeutics.  Dr. Hidalgo has chaired the AACR and ASCO Program Committee in </font><br><font face="Arial" size="2">developmental therapeutics on numerous occasions and is frequently invited to speak at major national and </font><br><font face="Arial" size="2">international meetings.  He chairs the Pancreatic Cancer Research Team, a nonprofit organization focused on clinical </font><br><font face="Arial" size="2">trials in pancreatic cancer, and is also a member of the NCI Developmental Therapeutics Study.  Dr. Hidalgo is one of </font><br><font face="Arial" size="2">the inventor&#8217;s of the BPU sulfur analog compounds that the Company acquired in February 
2007.  </font><br><br><font face="Arial" size="2"><b>Chief Administrative Officer: James M. Martell</b> founded the Company in 1985 as a small merger and acquisition </font><br><font face="Arial" size="2">public company under the name &#8220;International Group, Inc.,&#8221; changed in 1986 to &#8220;Champions Sports, Inc.&#8221;  Since then </font><br><font face="Arial" size="2">he has served in various capacities as Chairman, President and CEO until 2007 when the Company changed its </font><br><font face="Arial" size="2">business direction to focus on biotechnology.  Mr. Martell has served as President and CEO of Champions </font><br><font face="Arial" size="2">Biotechnology until March, 2008.  Since 2004, he has worked and collaborated with Dr. Sidransky in the development </font><br><font face="Arial" size="2">of personalized oncology information panels after his close friend was diagnosed with cancer.  Mr. Martell currently </font><br><font face="Arial" size="2">administers and oversees all of Champions
 medical information panels.  He was a partner from 1983 to 1987 in </font><br><font face="Arial" size="2">Tomar Associates, a consulting company specializing in European-American joint ventures, venture capital financing, </font><br><font face="Arial" size="2">technology transfer, and corporate finance.  From 1981 to 1983, Mr. Martell was a partner in International Group, a </font><br><font face="Arial" size="2">company involved in promoting national and international business development.  He held various administrative </font><br><font face="Arial" size="2">positions from 1973 to 1981 with the U.S. Department of Energy.  Mr. Martell received a Bachelor of Science degree </font><br><font face="Arial" size="2">in Chemistry in 1968 and Master of Science degree in Geochemistry in 1973, from George Washington University. </font><br><br><font face="Arial" size="2"><b>Chief Financial Officer: Durwood C. Settles </b>served as a Director of the Company from March, 2001 until March, </font><br><font face="Arial" si
ze="2">2008 and has served as Treasurer since June, 2007.  Mr. Settles is a Certified Public Accountant in individual </font><br><font face="Arial" size="2">practice since 1983.  From 1973 to 1982, Mr. Settles was Manager of Special Projects and served on the audit staff </font><br><font face="Arial" size="2">with Coopers &amp; Lybrand in Washington, D.C.  During the period 1974 to 1986, Mr. Settles was Treasurer or Controller </font><br><font face="Arial" size="2">of various national, state, and congressional political campaign organizations.  From 1964 to 1973, Mr. Settles was </font><br><font face="Arial" size="2">an owner and executive of a private manufacturing and marketing business after serving two years as a Group </font><br><font face="Arial" size="2">Pension Management Assistant and Computer Files Service Supervisor with the Mutual of New York Life Insurance </font><br><font face="Arial" size="2">Company (MONY) in New York.  Mr. Settles received a Bachelor of Arts degree in Economics in 1964 from 
Davidson </font><br><font face="Arial" size="2">College and completed accounting studies in 1973 at George Washington University.</font><br><br><font face="Arial" size="2"><b>About Champions Biotechnology, Inc. </b></font><br><br><font face="Arial" size="2">Champions Biotechnology, Inc. is engaged in the development of advanced preclinical platforms and predictive tumor </font><br><font face="Arial" size="2">specific data to enhance and accelerate the value of oncology drugs.  Our Preclinical Platform is a novel approach </font><br><font face="Arial" size="2">based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the </font><br><font face="Arial" size="2">resulting xenografts (Biomerk Tumorgrafts&#8482;) in a manner that preserves the biological characteristics of the original </font><br><font face="Arial" size="2">human tumor.  The Company believes that these Tumorgrafts closely reflect human cancer biology and their </font><br><font face="Arial" size="2">res
ponse to drugs is more predictive of clinical outcomes in cancer patients. </font><br><br><font face="Arial" size="2">We leverage our preclinical platform to evaluate drug candidates and to develop a portfolio of novel therapeutic </font><br><font face="Arial" size="2">candidates through pre-clinical trials.  As drugs progress through this early stage of development, the Company plans </font><br><font face="Arial" size="2">to sell, partner or license them to pharmaceutical and/or biotechnology companies, as appropriate. The Company </font><br><font face="Arial" size="2">also offers its predictive preclinical platform and tumor specific data to physicians for personalized patient care.  In the </font><br><font face="Arial" size="2">course of this process, this permits us to evaluate oncology drugs for companies by using models that integrate </font><br><font face="Arial" size="2">prognostic testing with biomarker discovery. </font><br><br><font face="Arial" size="2">Champions Biotechnology is dedicated to enh
ancing preclinical development tools, accelerating development and </font><br><font face="Arial" size="2">valuation of oncology drugs, and advancing personalized treatment with a goal to improve the lives of cancer patients </font><br><font face="Arial" size="2">globally.</font><br></p align="right">
<div style="position:relative; left: -5"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
<p align="right" style="border-bottom:double">
<font size="2" color="#000080">3</font></p>
</td>
</tr>
</table></div>
<p>
<br><br><font face="Arial" size="2"><i>This press release contains "forward-looking statements" (within the meaning of the Private Securities Litigation Act </i></font><br><font face="Arial" size="2"><i>of 1995) that inherently involve risk and uncertainties. Champions Biotechnology generally uses words such as </i></font><br><font face="Arial" size="2"><i>"believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-</i></font><br><font face="Arial" size="2"><i>looking statements. One should not place undue reliance on these forward-looking statements. The Company&#8217;s </i></font><br><font face="Arial" size="2"><i>actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen </i></font><br><font face="Arial" size="2"><i>factors. See Champions Biotechnology&#8217;s Form 10-KSB for the fiscal year ended April 30, 2007 for a discussion of </i></font><br><font face="Arial" size="2"><i>such risks, 
uncertainties and other factors. Although the Company believes the expectations reflected in the forward-</i></font><br><font face="Arial" size="2"><i>looking statements are reasonable, they relate only to events as of the date on which the statements are made, and </i></font><br><font face="Arial" size="2"><i>Champions Biotechnology&#8217;s future results, levels of activity, performance or achievements may not meet these </i></font><br><font face="Arial" size="2"><i>expectations. The Company does not intend to update any of the forward-looking statements after the date of this </i></font><br><font face="Arial" size="2"><i>press release to conform these statements to actual results or to changes in Champions Biotechnology&#8217;s </i></font><br><font face="Arial" size="2"><i>expectations, except as required by law. </i></font><br><br><font face="Arial" size="2"><b>CHAMPIONS BIOTECHNOLOGY, INC. web site:  </b></font><font face="Arial" size="2" color="#0000ff"><b><u>www.championsbiotechnology.com</u></b></fon
t><br></p align="right">
<div style="position:relative; left: -5"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="637.333174" colspan="1" rowspan="1" >
<p align="right" style="border-bottom:double">
<font size="2" color="#000080">4</font></p>
</td>
</tr>
</table></div>
<p>
</p>


</body>

</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>cbi8k_04012008-pressrel00.jpg
<DESCRIPTION>LOGO
<TEXT>
begin 644 cbi8k_04012008-pressrel00.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"`!(`.$#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^_?`]!^0H
MP/0?D*,#W_,_XT8'O^9_QH`,#T'Y"OYZ/V[_`/@O+X+_`&;/BQXD^"/P.^&E
MM\7?%G@+5;S0/'OBG7=:;1O!>E^(;2(I>Z%H3:9'?7^NWVB:@1I^N2R?V=:6
MVH6U_IT4DLUJTI_H1N%E:WG6!MLYAE$+$G"RE&$;'.1@.03D'CVK_+H^+UEJ
MVG?%KXIZ?KUO>VFN6/Q)\=VFL6NH1SV]_;ZI;^*=5AOX;R"X"7$-U'=)*L\4
MRK+'*&5U#`BOW+P-X%R'C/-LYGQ!3EB\+E.$PTZ67QK5*$,16QM2M3]K6J4)
MTZ[IX>-"7+"G."E5JPE.7+#DG_,_TE_%#B?PXR+A^GPK.&"QN?8W&TZV:U*%
M'$O"4,!1P\W0H4L1"K1]MB98F+]K4IR]G3HS4(\T^>G_`%\_L,?\%[O!W[0_
MQ7\.?!?X\?#.S^$>O^.=0@T/P3XQT#6Y-9\(W_B6\EM;?2O#^N0:C#:ZAHUQ
MK=S--:Z9?127]H;X6=C.(S>_:(/Z),#T'Y"O\KSPMIGB;6O%7A;1O!+72>-=
M8\3^'=*\&/9/(E['XNU'6;*S\,R63QAI$NX]<FL7MGC5I$G6-D5F`%?ZH>![
M_F?\:T\<^`\@X+S+(ZO#]*6$PV<8;'.M@'7K8B-"M@:F%7MJ<\1*I5C3Q$<6
MHJ#J2498>;2BI6>?T9?$[BKQ%R3B.EQ56ACL5D&+RVGALTCAJ>&J8JCF-+&3
ME0KJA"GAZE7"O!Q?/"$:CAB(>U3?+*1@>@_(48'H/R%&![_F?\:,#W_,_P"-
M?A)_3@8'H/R%&!Z#\A1@>_YG_&C`]_S/^-`!@>@_(48'H/R%&![_`)G_`!HP
M/?\`,_XT`&!Z#\A1@>@_(48'O^9_QHP/?\S_`(T`&!Z#\A1@>@_(48'O^9_Q
MHP/?\S_C0`8'H/R%&!Z#\A1@>_YG_&C`]_S/^-`!@>@_(48'H/R%&![_`)G_
M`!HP/?\`,_XT`&!Z#\A1@>@_(48'O^9_QHP/?\S_`(T`&!Z#\A1@>@_(48'O
M^9_QHP/?\S_C0`8'H/R%&!Z#\A1@>_YG_&C`]_S/^-`!@>@_(48'H/R%&![_
M`)G_`!HP/?\`,_XT`&!Z#\A11@>_YG_&B@#.U;5;+1K.2^OYUAA5DC0,R*TT
MTK!(H(0V-\LC'"*,GJQPJL1YI-XZGE972Y%LA(FBC^S$.D3@.K2B5/G58F<,
MSH(V$4[JBRPJR>5?'GXC:)HWB;2_#.JI,XM=,CU<;4F:+SKN>XB3*I&RLT<=
MD"I8G+3;``IF*XOP=\3Z!XT\;PV-I`DGV"PO-7F$Z-S+#.D,&-\4>\K-<FY4
M9)!$1PFS97MK(<9_9RS*4*L*'L95G-X3&NER:>SMB8X9X2\VTM<0E&34'[Z<
M%X,L^PZS%Y;&"G5^L1P]UBL#!IRC3YKX>>)6+;@W-M+#WE",904HR4W],6'_
M``E5_''*UY]AB:-9%:>TM?-DWJ-JO`8=\;#:3(&,3*92`&P!'_$U_P`%@_V3
MM+\'?MV?$_Q!IEQ<Z9IWQ8L/#OQ0EM=/M[8VG_"1Z]8?8?&-Y#'(@>'^V/$N
MDZAK]TK23,^HZO?2ATB>*"+^GG]JS]MOQ)\+M:U#X>?!KP98>+/&&GQO#K?B
M77[Y;3PUX;OWBCDAL8;!'BO->U"-9`]U%%<6=G:%3#+=&X;RD_`/XP>"OC=\
M>O&]_P#$3XKWMIXK\5ZA%%:&]N/[/MX+'3K9I&L]*TVSM;F&WLM.LS-*8((U
M)W2222.\CLQ_;_!#*<5DV:U.(,SSO#9#E>-RVMA/8K%89YIC(U:M"M0J0PM6
M-6GAZ4:E&$_:8J,*LZ4OW%.4*RJK^.OI:<39;QGPG_J/PCCL)6XJRWB#"8R6
M9U,3EU'`94\''%87,,'5J8JLJ]?$585W1E2P^'J4(U(WJUXU:"IGYW?L2_LZ
M7VL_M/\`PK@\/3ZCJWB:QU'7-;\+V$D]II+R^)M`\*:]K/AY[6_66W,%_;:Q
M8V5S8$3PL;N&$1OYQB1OZQ_AM^UC\>/AI>-X:^-&EGX@6UG'$9+B\TJ+P%\2
M[6W>5UWR:,]A;>']:CC1)(+2=Y=+%^]O(DNJRW<-S-+^"?AWX#?$/PAKND^*
M/"HC\.^)-!OH-3T77='OH;+4]*U"U??!>65U'>[H9XFY5L%2"R.KHS*?V1^#
M?[4WB3XG/I'PW_:Y\":'K7]I74>FZ3\8O#9T[2M2T*\O-MK92ZUI%L^R"`7,
M[M+J>ER)8P^:&N]*CBA\]_RCZ7WA/XA<?YQDOB+X,^,-;`9[PSP]+*7PMFM7
M`8K(LZA#,,3F,I8W*Z=.G0JUJJQ+P\<92IXG&4H1IPIX2JN2M0OZ''B'EOAK
MPIF_A]XEX3),5C\_XK6:X+BC#XC`5G[/%8'+<OH9=7K86O#'8*.%K86=6DZ$
M(8.L\95J9A6<:-%0_7_X=_%#P7\4M(_MCPAJXO%C*I?:=<Q-9:QI<S*&$.HZ
M;.JW-NW.$DVM;RE7$,TFQ]OH.#ZG]/\`"OR=\8^!_&W[._C6PU71=2DCAG_>
M:%XELH?*MM5M89?,ET?6+=287<+@W6GS%XKB"0W-JZMYGD?H#\&_B[I?Q7T!
MKF,16/B+2EMXO$.C!RS6LTPD$-Y;%MKRZ=?&"=K6;;E7BFMY/WL+Y_F'PT\4
ML?Q#C\5P9QSEF'X<\0<IBXXS`T)S67YLJ4'4JXG*E6J5JD>6CRXF6&^L8N$\
M+..,PF+Q6'565#^],?@:=)+$8.4JF$J:QYFI3I7;M&<HQBI);*;C!WO&4$U=
M^PX/J?T_PHP?4_I_A1SZC\C_`(U^._[6'_!;;]D+]EOQQKGPQ27Q+\7O'_AF
MX:P\1:5\.X+&?1=#U:)XA=:)J/B>^NHM,_M>S$A%Y96(OGLKB*:SO3:W<9BK
M^A,DX>SOB3%O`Y%EF*S/%1@JDZ>%I\RI4W.-/VM>I)QI4*7/.,75K3A33:O)
M'QG$?%/#O".`_M/B7.,#DV"<_90K8VLJ?MJO)*?L</22E6Q-=PC*4:.'IU*L
MDO=@S]B,'U/Z?X48/J?T_P`*_-K]BG_@J?\`LO?MQZU>>"_AUK&K>%/B99:;
M-K!^'7CBVM],U[5-+LUA.I:CX<EAN9[+Q!::8T\8U#[#*;NSC9;BYM(K9TF;
MN/V=?^"A/P2_::^/'QH_9Y^'^G>-K7QQ\"[_`%_3O&-SX@T6UL=#GG\.>*KK
MPC?'1[V'4[J6[C?4[21[=I+:`R6Q64A&R@WQ?"G$F!K9G0QF2YAAZN34*>)S
M2%7#SC]2PU:?LZ6(K2?N^PJS?+3JQ<J=1Z0DSFP/&W"69X?)L7@.(<JQ6'X@
MQ%7"9+4I8NF_[2Q5"+G7PN&BVISQ%"*<JU!Q56DD^>,;'W;@^I_3_"C!]3^G
M^%?"7[1__!0GX)_LO_'CX)_L\_$/3/'%UXV^/,^@VW@N\\/:+9ZAH44WB#QA
M#X)M$U>\EU2UN++R=6GAEN66UF5;.02QF1T>-?NBXGBM;>>ZN)8X;>VADGGF
MD(6.*&%&DED=BP"HB*69B0%4$FO,Q&78_"X?`XO$82O1PV9TZM7+ZTX.-/&4
MZ%>6&K3P\O\`EY&G7A.C)K:I%QW1Z^#S?+,?B,QPF"QV&Q6)RBO#"YG0HU8S
MJX#$5*4:\*.*BG>E4E1E&K&,[-PDI+1IDN#ZG]/\*,'U/Z?X5^:O[)7_``5,
M_9U_;&^-GC[X%?#.'Q18^*O`^F:WK4%]X@M+&VT?Q7I7A_Q!!X?U&\\.3P7T
M\]TJ27=I?I')!&[:?/\`:#M$;K7UM^TI^T%X*_99^"_C3XZ_$6WUN[\'>!;:
MPNM9@\.6,6H:R\6HZI9:1!]CLY[JTBF*W5_"TH:XCVPB1QDJ%/5C,@SK`9E0
MR?&Y9C,+FF)>&6'P%:C*GB:SQCBL*J=.23DZ\I1C3MO)\OQ)I<&7\5\.9KD^
M*X@R[.<#B\EP7USZWF=&LGA,/_9ZE+&NK5:2C'#1C*563]V,4Y7MJ>Z8/J?T
M_P`*,'U/Z?X5\E?L<?MH_!G]N+X9:E\4?@Q>:N-+T3Q3J/@_7M#\2V,.E^)=
M$UBPM[*^C&H:;#>7BQVNI:;J-EJ&FW:320W,$SH&%Q;74,/@7CW_`(*M?LR>
M`?VL])_8WNAXUUSXIZKXL\*>"#?>'M%L;_PIIWB;Q:UNMMIFHZL^K0RP3:<+
MNW_M55M)&M6<Q[7D1E&U'ACB'$9AC\JHY/CZF8Y72K5LQP<<//V^"HX=Q5:I
MB86_=0IN<.:4K+WDTVFC.KQAPK0RW+,XJ\093#*LZQ%'"91F#QM%X7,L3B'-
M4,/@ZRDX5ZU65.I&%.FY2<H2C;F31^F6#ZG]/\*,'U/Z?X5^8_[9'_!5W]F[
M]B#XG:7\*?B[I7Q'OO$FK^%-/\8VTWA'P[8ZMIJ:3J.H:EIT*S7%QK-C(ETL
M^EW)>'R<;#$P<[^.*_9K_P""T_[%G[37Q/TGX1^'==\6>!?%GB2:&Q\*?\+(
MT2V\/Z5XFUF<E8-`TS5(=4O[1=:NF4K86-Y):OJ,K1VU@US=R)`>NGP5Q;6R
MM9W2X>S6KE+P\L6LPIX2I/#/#0YN:LJD4[TX\LG*25DHMNR5SBK>(/`^'SI\
M.5^*\BHY\L53P3RFKF.'IXY8NKR>RPWU>4U/VU3VE/DA;FESQLG<_6W!]3^G
M^%&#ZG]/\*^$OC=_P4(^"GP%_::^$W[*?C+3/&]S\2/C)!H5QX5O-&T6UO/#
M<2>(=:U+0K(:GJ$NIV\]JT=YIDS7`2TF$<#QR*7)*#V_]I+]IWX+_LF_#:]^
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M8G6Y_P!'G\F1)`O?G7!_$_#KPJSO),?EJQKBL+/$4K4JTYQC)4HU8N5)5HJ2
M]I1E-5:3O&I",HR2\[AWCK@_BV&-GPWQ%EF<++G+Z['!XA3J8:,93BJE2E)1
MJJA-TYNCB%!T*\5ST:E2#4GZG@^I_3_"C!]3^G^%?"'[$W_!13]GG]O.Q\9S
M?!B_UVRU;P+/IPUSPMXRL;+1?$HTW5H3)8:]::7!J5_)<:)+.DU@U^K".._@
MEM7VOL+GCK_@H5\$OA]^V)X(_8EUK3?&\OQ;\>VVB76CWUCHEK-X2BAUZPU7
M4+,WFJOJ<=Q$RPZ3<K,JV,FQVC`W`DCFJ<-Y]2S#&935RG'4\RR_#5<;C<%.
MA*.(PN$HT8XBKB*U-I.%*G0G&K.;T4&I/0Z*?&'"U7+,NSJGG^5U,IS;'4LM
MRS,(8NE+"X[,*]:K0HX/#5E)QJXBK6HU:4*46Y2G"44FT?=^#ZG]/\*,'U/Z
M?X5^:G[;O_!5']F;]A;7M*\#?$.[UWQ?\2]8T==>C\`>![:UO]6TK1[B26'3
M=1\2W%S=V]KH5MK$UM=II2W+/=WJVL\\-JUK&\ZYO[&/_!6C]E;]M?Q8/AQX
M%U'Q#X,^*$MG<7UAX$\=:=%8:AKUOI]B^H:L_AN_L[F[T_6!I-M%/+>PK+;W
ML<$$MU]C^RKYQZH\&\52R5\11R',Y9*J;JO,5AINA["-^;$:?O/JT;/FQ/)[
M"*3;J):G'4\0."J7$2X2J<391#B.4X4EE,L7!8EUZBC*GA;O]U];G&47'">T
M^LR4HVI/F5_T]P?4_I_A11SZC\C_`(T5\T?8'Y;_`+7PEL?C#%(]R(UU'P?H
MUU!&+AHR([>\U2SD<J-HYEC(R"Y'&2H(!X+X!?$&R\#?%3PYJ&J7T,6DZS*_
MAG49Y[E-MLVM;+?3;HO)D1QQ:NMA'=2;XD@L9;F[E<QVQC?N?^"G>G7/A?P=
MX,^,\>DS:EHWAG4)?"?BUK1`)]/LO$<]O_PCNJ7,ZB21=/BUR,Z.Z^3(!?:_
M8-NBC,SU^+9_:0\,'_F"Z@/<7+@CW!%ED$=01R#R*_:N&>#LZXJX=H8G`1Q>
M*P;A4P%:G2<)PHUL/RTY4FJF(BHS5.5&O!.FU&-6G*VJ1_%_B3QSF_`WB+CZ
M<<!ELI4\5A<XRVOC,]PF7_6<-B8TZG,\)BI1JRH^W6*P56=.HH5)4:T:<J4H
MN$/T<\1Z?+KWB/Q!KNH:3!)?:YKNL:O<O>QPRSB6^U">Z:"2[N+:`7)M5F2V
M20+&3'''B&),(N3_`,(Q!S_Q)M.POWB;:V!4\`AD\GS%VL=C,R!-_"LV5)E_
M96_:*^'/QOF7P+K=OHNF?$.PM?+T^/5[.%)?&]G"EY)#>V%R8[?SM7TZWCB@
MUVQ#1S7A>'5K;S93<F/[N@\`Z?#!%<3>'=+N?.VHP&DK;?Z/OC6TG,,L&446
MGD/?0VZHT:NXS(_G;>/.8X3AO'RRW.O[4P&+HPC)X2I1Q$>>G45Z-6A6C!T:
ME'EBU&I3E*$W"44H3C.%'[;AWA#(N-<NCGV25LLS:ABJE1U9T'@*E2GC(QC+
M%8?%/DDEB*56K&5:TY1FITZE"=6A4A6J?!X\)*<8T*Q.<8Q90G.<],6WL<>N
M#Z4Q_"$<L;(VAV85UQN2TC1AG&&1UMPR,,@HZD,K;64@X(^_9O!L$0OF@\':
M.ZVJ(\'[EXW\P[&2*5?LZD.(9C/OB'DJ&:(2EV9A)'X)M6ELHO\`A#]($<RA
M;IQ;*%BD`#)%#^Z/FX2,,#M`VJK+DA5/EOB#AN/(_;9E[VL6JM=ZQ47HUA;7
M6FS>J=G?E/;_`.(3Q5F\KPUI*33?]EI6CR\SNVE:TKWVMK=K5^O7F@I\8/V>
M]%2^5;C6Y?">G:C:79B)DA\4:-:+'.\<*@DI<7UK=64T//F6]Q(@`<JR_$WP
MJ\6W'@'QOH>O1![>PDN(=/UZ"-&1+C2+R18KGS51`':R9DOXLAB)+;:F/,)/
MZ+?#](_#_P`.X5DA6VMM+@U:;R/,01Q(D]U<S(F,^0C3-*RV[!C:[_LX+)$I
M/QJ-/L#"(S:PLIB$9W(A9EV!3O).XLP^\3\Q))/)K^9/$7(</B.)LNS[)Z>$
MIX[#U*SI8RO&5.L\/A,6JV7+GITY58M*OB(S2<6X3=.3E&T5_4'">62QF7_5
ML;B*E*6&H82%3DI1Q/M:M2CRUXRE[>A!*,J5^:+;E*;:BMSVC]N7XQZE\!_V
M./VCOC#X=<#7_"'PA\77WA2Z0>=';>*-3TR31O"FHR(I3SK2QU_5-,OKE$D1
MI;6"54E1F5U_#S_@@_\`L)_!3QQ\`M9_:R^,W@CPY\6/'_Q'\;^,]!\+S^/+
M2Q\76GA[P[X9U5='UC4XM+U6WN;6V\6>(_%EGK\NH:O=13ZH=(BLUL[JVM=7
MU&&Z_>_XB?"K2OC]^S!XP^#7B1MVF?%3X/:OX'O+N5%G>RD\1^%YM,M=6B#D
M_P"F:3>3V^IV<HP\5Y:0S1E716'\IW[%'[?'Q*_X(]>(_B=^Q]^UM\*?&&I^
M#M/\77WB7P_?Z&UO%>Z5J&IVENDVI^&8M5>VTS7O!_C2WL[/7+5K35H7L+^>
M^>56O)K^%/ZTX`CF>=>'?$^3\*RG3XIQ.9Y/F>*PN'Q4</CLQX>AAJL9X;`R
MYJ52H\+CYQJ8FFJB52E6C347*:A/^7/$^KE60>*O!&?<;T(5N"L-D^>Y/A<=
MBL++%95DO%>(Q5"=/'9E>%6G3CC<NHRPF$JU:452J1J5>=1A4E2_IP^#W[`_
M[*7P"^-7B_X]_"+X0^&?`_C[QEH-OX?NWT6V6VT31;03RSZI+X3T,(;#PK-X
MB)LX]?70X[*VU&/3;/=;HQNFN?Y/?V=/V^_AS_P3\_X*'_MY?$+XC>#/&GC:
MR\;?%;XN>%--T[P6WAZ.ZMKJV^,'B#5)KJ]F\0ZSI$"P>4BQQI;FYE>1B76)
M5#-^XO\`P3__`."JOQ/_`&[_`-J7QYX2\-?L^ZOX>_9JTCP4UWI/C^XG6:_\
M/>)=-NR8V\5ZD?(TBZD\9P7<5OIGAW0VO=0T5M.-W<27EE+>WEK\"_\`!*7P
M3X/\;_\`!4+_`(*.Z;XV\'^&O%VG0>,_BI=VMIXH\/Z7KMK;W(^.&O1_:+6/
M5;2ZBAF,;LC20A'9"58D#`^IX8PN8Y)A_$NEQ]1Q6:UJ/"7#\\=@7G$9XUX)
MXNDL-@IXZG+%2PE:A3]G&5&2<X*.W+4C5E\AQECLKXDQ?@WB?#.O@\FPV)XX
MXGCE68RR&K'+5C8X&O\`6LPI99)Y>L7A<3B?:RC7A.%.I.;F^:4)TCXT_:3_
M`&_OAW_P4(_X*&?L$?$'X<^"?&?@?3_`'Q+^$_@[4K#QK+X>FO+V\OOC7H&M
M17=D_AW5M6@^S+#,89%N9()A*N41T;<O]+7_``5O_:9E_9>_8:^+_B72+S[%
MXW^(6E2_"'P#/%<1Q7EAK_Q`L[S2+O7[!7(>6^\+>'VUGQ%8K'%<+_:&G6?V
MF$V9N&7\<O\`@K+X&\&>!O\`@I__`,$UM/\``_A#PUX0L;OQ'\,KZ^LO"^A:
M7H5K<W/_``T#HENEW=P:5:VT4TWE1I"D\RLX1/+5MH(K;_X+#GQ1^W#^WO\`
MLO\`_!/3X;ZW]BAT%+CQ'XZU)8)M0T[PSJ_BJQ&I7FO:M:VQ7SI_"?@'2)KN
MTM)9H1)<>(X+0SVBZAYU=SRW(^(<7X35\-@JF5<*Y9D?$6?X_#8RO/,G@\KR
M;.\7BL5'$XA4Z<ZT,5B:2I_P[QCBHTU&IRI2\;#YWQ)PEDWCG"MBZ6=\:9KQ
MADO#>5U\!@EET,QSO/,HP>!H2P>#=>M'#SH8>I6KP4Z\H>UPMYRBI-+X&\&?
M"#Q/_P`$I?&W_!,G]L76XM8@\/\`Q:\/W"_'4>?,MOHP\5Z]J-WJ.A_9;*&]
MD)T?X0^)M`U)-,47+Z[JW@34KBU@AO'D>'^DW_@LO/#=?\$U/VC;FWEBGMKC
M0/"4]O/!(LL,\,OC;PU)%+%(F4DBDC97CD1BKJP9200:_#;]J3_@A/\`'/X9
M?L_?$CXFW?[6&K_&"W^$WA'5?'5M\/M2T+Q$\-[:>&]/GGU(Z8^J>+]3M--N
MK+0?[2EBFBLG<6\<MLBE)BA^A]2_:,?]HW_@WN\>7^J:@^H>,_ACX?\`#OPC
M\8^=)-->?;O!WC?PI!H-U<-,3+(^J>$KG0+\/RK-.Z(2$%7GCP'$^8<!<89=
MG=+B'%Y;QM@<DSO&T,#CL!R4<QSK^U\EISPV.;J4Z6#C5Q>!IUU>G4C]7HQD
MI4E37'PM+,N$,H\4N`LRX5S#A#`9MX=9CQ-P_EV88_+\R<\5EO#\,CXBJPQ>
M7U:U*I5S&O3PN93H.HIT9+$2=-0G&<_RK_8Z_:3^,O\`P2GU+PW\7+GP_)XY
M^%'[7/[.>K^*O"5I!<C3]$;QSI$^O:;X:_M)W6]\S5/`_C#3CI7BBQBDL;F[
M\(>*[+7+:59%32JX?X%?#OXJ^&_V\/V"/BS\9=1NK_QK^U/\3O!/[14[7]J;
M;49+#Q?\8O$FE6FK7A$S(W_"2MH4_B.QMX;:P@L-*U*PLH+80PQL?Z(?V9/V
M&_A7^W)_P2F_8@\$_$D/`W@F?P_XTT[6+.(_;8]+L/B#J1\:^%"\K"1+/Q;X
M674]"G,;+%:WLUCJ2QR&Q$,GRQ_P4QTRRT7_`(+,_P#!-;1=(TV/3=&T7PI\
M"=-TRUM8HH;&SL;/XX_$6SM+"U@AP((;.VMX(XTV1Q")XTA+>7*(_I\KXWR_
M->(^(<NH9?1H<18G#<98+B;,E!1>-R_AVAC*&0QHQ;<(2JTZT98N5*,*LZF!
M@I\U'V<8?-YKX99QD/#G"6:8G-JV)X/RW-/#W,>#<GG4BZF7YGQ9C\IQ/$TZ
M\HQA5K0P]:C46"IUYUXTZ.8594U2E"JYX/\`P5(_X5LW_!9O]CL?&0^"$^%*
M^$_AY_PL`_$AM(E\"'PK_P`)+X].J+XHC\0V[:)'IDD1\MO[0\VW6X>"8303
M^6T/R]_P6*D_8,U+QE^S7HG[`6G?#"7XSGQ-<IK4O[,\&FV^BSQ7MWHR_#^S
M67P2(M#N/'X\7CS?#\VCM_;]BBS#4IX@VBK']'?\%8/A/X5^._\`P6'_`&2/
M@YXYCU*3P;\2/"/PW\(^)1H]T=.U(:7JOBSQRDIM=0$,WV><.B.CE')56CRF
M2R?LC^S+_P`$@_V*/V6/'5G\2_!/@+5/%'CG2)OM'AS7_B%K4GBF3PO=%$7[
M;H-C/'!IMEJ:;6\C519OJ5J))DM;N*.616^6I<4Y+PCDGAQG6-Q>?5LRPO!^
M*_L_)<#["&39A+$8G'X:+S:K.O&HZ=*5:<G2CAYMJG3G&ISJ4)?:8O@_BCCG
MB3Q8X;RW*N&J.1YAQ_E]3,^)\SG4GG>5K!9=D6-G1R?"QP\I.I6C0IJGB'B8
MTH2K5X>SBI.I'\H/^"D'VS_A]!_P3U_M'RSJ']@?"C[<8L>6;S_A8/BK[28\
M`#89M^S``VXQQ7*?\%&-&U']NW_@LY\"?V'_`!)K6H:%\*?`VCZ#9ZM86U_-
MY>HSW'P_UOX\?$'6;-$B1++6M>\$6FC^!],N'2[;3IM.^W)<"*_N;2'N/^"E
MX)_X+7?L",%;"Z9\,-Q`)"[OB1XN`R1D#.#C)K=_X+,?`'XV?`S]I_X/?\%/
M/V=-`OM4O/A]:>&[#XI0:1;7$S6-_P"%+K4+'3/$6OPZ<W]HW/A[Q;X.UF3X
M>>*IHT>"UT;3M.BN0MI<W+5U9'B*%%>&])8FC@LVQWAMQ+EW#6,KS5.EA.(\
M9B9TLMJ.I)M4Y23K4*4I7;JU81BG.43AXDPM>I_Q%^K/"8O,LBR_Q=X+S'BW
M+\+&=7$YCPI@L%A99K05.G"52M!35"OB(TY4VZ5"JY3Y%.$OU:^.O_!+S]C?
MXI_`'7O@YHWP&^&?@:>T\+7MCX"\6^%?#.E:#XI\(Z];VC/I6LV_B6RL?[6N
M)'U&*"?7/[1FOTUQ'NCJT5\\[EOQB_X(G_$_Q->_L:?\%"OV?]>O)+[3_@YH
M'B76?#A^T2_9;*/QQX-^(-GK]E9RR#_1[636O"$FIQ!%4"34KB9XE=F+W?C%
M_P`'$VE>/?@EJ?@SX*_`KQKI/Q\\;:#=^&%;4-2L]3T3P=JVKQ'3Y=2T--(A
MEUKQ1?6Z33OI-D=.TEQJ!M&F,J1R12?3_P#P31_8I^('[)W_``3T_:;\5_%S
M3WT3XI_M`_#SQAXTU;0+Y(Y-9\,^'--^'?B"'PQI/B`EW*:Y*=5U76-4TYY3
M_9]QJ7V*X5+V&[S\Y/`<1<-<`Y]E_'-2O#&9UQ#D$N&<MQ^-IXO'+&8+'QJ9
MKF=*/M\0XX2>$Y</*I[L*LI1?-RU8.?U5',.%.+O%'A/-?#*EAIY;D'"G$L>
M,<VRG`3P.5?V?F>5RIY%DV+E3P^%;Q]+'0>)5&/-7PU.+BHQE2JJG_.'^Q5X
MV^.7[$$'PD_X*%^!].;Q-\*)/B3K7P0^)^AV7G0^?ID>F^'M:U'PUKLQ22"R
M;Q3I-[+J/@K6&62TL?%/AN.VU`+Y]K;ZC^MWQ*^*'@SXU_\`!=G]C#XM_#K5
M5USP-\0O`7PE\3>&-66-XOM>FWWA?QV`LL3_`#0W=I<1SV%_;,2]I?VMU:R'
MS(7KVC_@BA\`O`'[3?\`P2]^.'P0^)NF&_\`"WCCXM>*]/F=,Q7^CZ@/"/@R
M?1]>TJ<C?;:KHVH);:C8S@%3+`$E62"26-_RE_8]^`/Q/_9<_P""OW[/WP$^
M*S7<^M_#CXI-I>D:@3=-HVK^%[[P_P"(M7T+6_#GV@LL&C:Y;7K:HEI`0EE?
MW&H6DRK>PW0K]+Q^.RCB#B'Q$KUG2PG$_"F1<7Y2U"*BLYX>Q.`K?4ZK2=GB
MLIQ#]A4G9.6'Q%)S=3W51_%L!DW$'"_#'A%2H*IC."^,N,.!<_?M)<U7A_BW
M"XVI1Q]"/NQDL#G>#?UJ$).HJ6)P56,)4(WCB/K7]OS5/%'[$7_!6_Q)^U[\
M:?V<HOV@/@CXRTS1KKPK)XAB>+PR89?`7AWP=+<:5KL^E:WX>T[QW\/[_1[J
M'3]$\3:=/#J&DW*/;_V5=:OIGB;0_P!1/^";WQ\_X)@?M'?'WQ3\4_V<OA58
M?!#]IW5_!5Q8:[X*UO1--\-WFJ:`U^E[K&M>$K'1;N^\)76IDP6W_"47WAIK
M+5;NTE275K>\B6:[C\W_`&O_`/@K=KO[-'[6OC_X*?M)_LGZCKO[,']BZ/:^
M#]9O]'L;[5/%%]:(UWJ?C"S76A<^$]?\/:CJ,T>F6FD?:[/4M)_LFTU&Z9+B
M^>T3\R_V++;P%^U)_P`%@OAI\9OV+?@CJ_P4^`G@#=XH\9V%K8PZ7HNFQ0^#
M?$FEZO/=V^ARRZ+HTGC35K^UTVVT&UNYXKR6&XO98RKW0B^065XS/^")XG/,
MNS#AZ65\`8>&7\4Y5GT*G#V;9;EU'VF"R;,LMCB%AZ>+Q#G[&IAH<U1XISDU
M3E&G1G^CO.\NX5\1Z.%X8S;*.**6=>)TXYGP9G?#56EQ5P_FF:5W2Q_$.3YU
M+#K&8C`4(MU:&)Q;J8:.&E3A1J23FX?VG<^@_,_X449/H?T_QHK^83^S#B/B
M5\/_``Y\5?`7BWX<^++8W?AWQCH=]H6J1!5,B07L11;FW+HR)=6DWEW5I*5/
MEW,,4F#MK^*O]I/X8?$;]EKXJZ[\*OB)X;E2>PEENO#/B)9732?&OA:29ETO
MQ-HTPMGBDCN80D>I6BR-/H^K)=Z7>+'/;X;^XO(]1^8KY._:^_8_^%O[8WPT
MN/`WCZ&;3-<TY;B\\#^.])6`>(/!FMR*A2\LVF1X;[3KDQ1PZOHMZDECJ=GN
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M6R6SO-/M9-.CU*#=)9Z]<3:F/['/Y,:=_P`$]/C;^R_^TKX4?XM^$AXH^&&E
MWM_JWA?XD^&XCJ7@_P`1ZY8VK_\`"):1JUH[7%_X8UC4O$#V,$>FZVGV'SA&
M(M:ND=9#^D'PX\?P>*O$6KVMS+$MKX;\2)9O$S>='.8@D4VIS(K^5(LMW%<1
M6@#96TBC1MK2.A_,OI@?2XX;R?BOPX\+LHX8P%/$\88=9I2XIQ&(6,IX>%;%
M5\+3P>#S2O2A#`+#/!U,7G6&IX>MC:KGEM#GP47B/;_GOT'_``-\3LKH<;\<
M>)>:9]E];),UEP[3X,4LOP&7RG"C@U_K#G>&P,%_:V'K3S+V&02]M'!.-#'X
MR+Q7/A:F%^K[OXS^*O#.JR:JFAP^(M(7RE>U6UM]-N[DP($9=+U&1[>VCOD_
MU%O-=W$FDRHD,+31VX@O8?M7P-JOA;XC^&K'Q?X.UN/5=`U$2I%<;GMKFWN;
M:Y6&\T[4;*ZM8;O3]2T]UDM[^PNX(KJUNXC'+&HXKY#^)NK>!9_!VF1:1I\5
MKJ4%L;;474PLES=K)=N1`45D\YYI9)'OK3*C9-8REPH%>'_L>?%_6="^*OQ.
M\'0/:ZAX$N_$7A2[U&%_/6[T;6?$,MIX-BU;2MK-#);R:Y_8ECKEHT,?^CSG
M6([HFPF@N?Y(Q7BQF'`GBGPWPGG.<K/LDX]H9C*A1E1E/%\-YG@,)6Q\*V%G
M2K5J[R+$8+"UWC*>.>+K8;EH8^GBZ.'CBHXK_0[_`%<69X'-<9A\++"5LLI0
MQKBK0C5P];'8?+Y49452A3I2=2K&O@J=+V:A!8BC46(E*E4I?ICXDN;]](;P
MSI&G:E=V[2RC5+K^R[](7`D$K6MM));1Q7D,DH8/<PF2&6)"AW)*&?S4^&-2
MP<>';LG!P!I,F2>P'^C]:^E_)F_YY-^:_P#Q5216[O(H=2J`[FR5YQC"C!/4
M^W2OZ`K8?$XVM&5:%7FERP3]FXTX+KRIQ]V";<K2E*5OBE)^\_D8\M*+Y,0X
MK=J$[7VZ*6KM;[T>>^,_'NA_`_X1W7C?Q5;:E<:+X,T;1AJ=MHMK#/J+"XN]
M.T>-;2VO+FQA9DNKV$NLMU#MB60@LZJC?.-C\7/V9/VG/%.D?#WXF_`Z:^UN
MXL;S7O!VG?'SX/:!?V6M#382VH/X9N-:A\06*WUE9SB:17>RDDM9V-LTX$RI
MV7[=+*/V4?B]\P`_LWPYSD<?\5IX;]\5\9^&_$>JI\;OV:M0U+X^>$?V@G.H
M:WX<T_P?X:L[72KSP%'K/@Z[:^\672:1J5[#=C2X+"'2)CJ3("MZYMX#())8
MOQCQ"\4>+>"O$O),AR7&8+#9)2R[P^Q&,I5L)E\Z^(7%/&V;\+YC)8JKQ'E>
M<TIX7`X/#5LOIY'DV>S^O:X^A3PDW-?8Y-PKE6>\+XW&X[#O$XEXC/XJ4YXF
M44\JR?`9GA%[)8'%8"2J8FM4CBI8_$8-RHO_`&6K]8BFOKGPM^T%^SI\-/@;
MX,\<>$?!Q^'W@WQ;J5]HG@?X:^#O`VD:?KVJ:W::A?VMUI.C^$O!9N-'6?[3
M9W<TES'=QZ8BO'+<7T37,8?G/!?[17[..GV7Q%\;^#?A#KOASXB:%-ITOC[P
M;H_PFTW0_BYJ=MXEUN*.#6;BVM%M?^$BT^ZU2^DU&^N1K5W/`?.O=0AAGFB$
M_P`A?`?7-%\`WO['?Q&\?F*V^'C>&/C3X/T[Q)>>6=%\->.=8\:ZE<Z?>7UP
MX:.U;4=+M[K3;:Z)3:;EF$JQ)-7U]'XH\*?$G]M+P'JGPSU#3]?A\!?"GQI:
M?$WQ%H9CGTU8/$-UIW_"(^'KW4X,P7U]'?0WFIP6WF2FPB,Q!C:YE0_)<+>-
M'B+Q7DO#^8RXJX4RG.>)I<`9%/A.ID^)Q6=X^OQEPAD><XOC:E3J9[AJN,P6
M59GGF(SFEEE/"5LOGP]P[F.'Q.:T<PKU\9E.^/X1X=R[$UJ']C8NOA\OIYYF
M&&QRK4Z6!P,,IS+&X.EE/NX2HZ3Q-+!4L).LL11Q2QN/P4H4_915+%X,'[3W
M[.WQ1\0OXAUS]G[QMJNM>!=-U^^7QCXR^$7A>\F\+GP);7?BNZTV'Q%?:E>W
M.BZG9WEBTUA9+/:M#K;P.QM9F\];WP^_:,^`GC7XD^'?$OA[]G3Q_I?C7QU>
MV%I;?%2^^#7AZPN9(M;LK33H-2U3QQ;7T^IG2YM*ALK66\^TW*/IL-M`JR6\
M44:X/@,K_P`,\_ML$[6`^)'[2W<<XMKS(S_]?C-<+^SGXCUR30/A7I<_[7W@
M+6+6X\%:1I-A\([;2="LO$/VVZ\)_8-'\-/JD.LRWS:CI5[+;)-(MDLUQ<6C
M9CC+D+G@/%3Q?IYCP+EF8<:Y;7H<1\.XC/L;]1X9R3`<N7OB'+\IGD]*&>\?
M95"-+V?UG$U<1@(YMC*M2K25/(ZOU9>V,3PMPS5PF<8[#9#2C6P6+A"$ZU?,
M,1-5Z67/%0QRGA<KQ,/;TI5HQ@\;6PE&$*>F(2G5E3^AO&7[;?P/T/5?$>@7
M.E^.O%_AKP]>/X?\<>,O#?@>\\1_#_0)Y%2/5+'6=11O,OX["WGSJL.E:;JZ
M^6SV\:7-P6MZZ_X:#]G+QQ+\3OA=X&^%G@F#PYX<NO!TWBS3(/`/A*R\%>*F
MU[0;/Q'X:U&#3K.W>VUF.VTW[&T5QJFFV\MK+%"MLK)''(/`/V<OC?\``KX;
M?LU1>$/B/K>B>&M<\`KXGT'XG^#M>C677+WQ'=:WK-SJSOI$L37&O'Q2US)?
MVPBCN5N(;U;>1_W3A>5\$>'OB?\`$?\`:`_:9UOX,_%VT^&VC3ZM\*M0GCN_
M!<.O-K-MJ?PUTJ[TB?RKR\TZ?3!;6A96M&BWGS@)!$T6VOJ.'O%[C%?ZB8NC
MQ!DG&%;C3&97B<WX'X-PF!R_B#AB&*X2XQXAA@ZM7-.+J-.;R[,<EPN#=;-8
M8''K$99F[C2C5Q-+`X'''<'Y+7_MV%7+:V7QR/"UZ.%SW.)UL1E^82EFF38%
MU8QPV55I0CC,'CL145+"RQ%"6'QF!4[QISQ6*^AO`G[5'P$M-#^$VF:!H][X
M!\+?$;Q+XN\#^"K,^'M&T+0=(UGPIJT^G7=E>6>BW\UGI%KJ^KDPZ5-;02V\
MUS=QO?FP,KN.Z\2^(/@9J'QDN-!\9^"_#=U\0/`7P_LOB-!XZ\2>$_#UZ-!\
M,V.L7RV[:;XGO8[C6--N-*U!K[4DBB2U@M3//=6\YN)I`WY9_"3X:Z-\6_`_
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M$$.BZCJ-K=2)I47A_P`9WUG/KNCV\\]_++I-U?0:1;0M=SM<26#S@3?6OA;X
MH^'O%WCCXC^`-,MM6BUGX87?AZS\03WMK!#I]S+XET.WU_3VTF5+J:XN85LK
MF-9Y+BUM%$P(@\^(K,WPK\<_C%\#?'7[(VG^$/`NJ:+K6O>-=&\'>&/AIX+T
MDQ)XBT_Q<E]HL.F1)I,(%WI=QX<ND$MZ&CB`CMWM=[I<@/N_"+XD>"/A=\?O
MVEK#XG>//#/AG5KA?@A#OU_6;'37U&[T_P"$7AV#4IK<74T9F$=RV)63<%=P
M"<FOMLN\8L[H\3\)Y)FO&W!W%609KCN'7B>*LLH1RS+LOPF><$^)F>/(%5JY
MUF>!I589APAD^8X"L\52Q;R_-9X7%8.4JN&QE7PJG">!GEV8XW+\DS3+LPA'
M'Q66U7]9Q6(JX'-^'L)/'SC3P.%K592HYMB</BHJG*E#%8:56$X)O#T?1_C7
M\:?V>/!?Q/L-.\1?"RZ^*OQ<\.:/9ZZ\WA'X8Z5XT\5^"=&BG>YTF[N]=OX[
M:;1EDGFN+G38+/46N(7=[IX+9+F&:?TN3]I;X(7GP9N/C5<^)X)OAUEM.O?M
M&EWTVJ)K9F6SD\)77AMK234_^$B^V2):-I#VA=RZ72LVGNEXWSM\$/BG\,_`
M7Q<_:/LO'GBG0-$UWQKXVM?B-X9\3ZM=V]II?BWX97_AO3!X<GT769Y3;7]I
MHR0WL$L$,O[AVD*Q@!Q'\F6M[I9>[^.AT^7_`(9PF_;:M_%Y(L98M+.BQZ'_
M`&%+XRETD1*'T9O$\EJ\EQ)#B::U8R(&PK^'G/CQQ9E]"&:T<]X2SFCF6)XS
MR^CPY##5_KGAQ@.&\SJ8#"<3Y_B*.=8K$8[)L%2IPQ7$D98/*</*MF&!>78O
M!852J8CLPG!.35.>E_9^8X.K&ADV*GF$)4U'B7$9CA'B:V68)2P"IPQU6?MJ
M&5N4\1*"P^*^N4J]1.-+Z+\(_%K]C30=3\0^.M!_943P+\0M%T2^\=!H?V??
M!7A?X@Z]X7$D*^(/%.B:Q!#9_P!I1Z;%?FZUJ$:XNKSV[2M9V6HO(L<GUKXX
M^/?POTGP3\/]:N8;GQSH_P`;KK1/#W@?P[H=EINJ7?C*+Q?:(T,2Z=K%[IVG
MRZ9]BNT_M@WMPD%K!.4ND(+)7S9IGQ>\5:Q^U#X+\"1_%/X<_$GX;_$6U^(%
MTGAOPYH&FWFH>'/"=GX<-_I-GK>N127#F/4YI+==KK$E\MO(LBN!M''?`KX<
M^"?AO\<?C5J/C7QE_P`4%^S3J=GI7PJL_$]W!;Z'X`L_C"S>(=1:.XN&$"2P
MS7-CX:TB;]W(EL/WC27%RK+ZV%\5_$/,,;A\NP^?93Q%#%\58O@2IQ/F&6X+
M**'#6/RG)\%QYC<ZJ4\'Q3Q!@,\RNMP+6S>>#JX7,,O6'SK+\KP>/R^A]8S.
MO0Y8\*\.82A5JT\M>7-9?1SRGEF">)JO-*&+Q$\CH8/][EF7UZ&)IYS'!4YN
M5*K[3`5L1.AB:\J6&C4^T+W7/A7\!+KX>^$-#\"Z?X1B^+7C9?"^DZ=X'\,^
M']%TN/Q$V@WFI&]UR#37TR!473=%:U:]MX;^X)BMH`A@573CO#/Q(_9]^*NF
M^*OC;8^#M$UGQ)\'[WQ'I>JZGJWA'P_-\0_#=UX/&I&2+3=2N!/<VT5Y:B[N
MM$GM-8BMI[>]E1Y;6<WUO#RO[35S;W?Q!_8WN;::.>WN?C]#/;S1N'CFAE^'
MOB^2*2-@<,DB,'1APRD$<&OA#3O"_B'X<_!_7?VA/`UN]WI.O:K\<OAI\<M!
MM%#-J/A2^\>>,K30/',5N)(EN-7\(7[V=I++GS1HEQ/N/V>.ZW^AQKXT<9<+
M<;9_0P]"GF?#N2X3.<7GE?#T\15SK"Y)AN%^!L7+-Z4J52;S&EEN8\45,;FN
M$]FG5R&CB9T.>OA*5'$QEO!>19AD&6>TIJAC\77PM/+Z4X4E@9X]YCG\8X=T
MY4[8>IB*&61HX2K"SAF$Z2FXTZU24/O+XO\`QT_9SU?X=^`+GXE>`/\`A:-K
M\6])M-:\&_"S4?AYI7Q`\0:W82QVMY)<3^';^+4=$MXM-6>"6\FN[Y(A(NRS
M>[N%6,]C^S%XN_9_\3>%M;M/@+X%T7X9VGA_5Q9>+/`FF?#VP^'%]X?UNZB:
MXCCU;0M+TZQL'N+N!3/'=VDEY#,@8?:/-22-/C_X$^(O#?PY^*?P:\1?$K4+
M+1=(\9_LC_#OP]\.O$FLR)#I%KJ^B:AJ-[XJ\/07LV(-/U"]@O--U#,C0G48
M3%`DDKVZQ+]N^%?VA_@5XB\0WFA>&/%^BW&KZAXR7PDLEG;2+;>(_%8T)-5,
M&G:G#`;/6)H-)M6CFN8[B3R38O;R,HCB#^SP+XFYQGN,IU.(./.$<FP$\:LJ
MEP%7H+#9S7Q7]D9=B<%F<<;B<]P\X5\SQ&(>9X2BLEQ.$J9-CL!A:%26+OC9
M\F?\+Y7EU;$?4<@Q^+QD8/$0X@AR5*$*"Q5:E4PTH0R^<Y4<)3I2PE6I+&TZ
MD<?0Q,Y-T.2A#WS(]_R/^%%&1ZC\Q17[R?&BT444`,DBCF1HYHTEC88:.1%=
M&'HRL"I'L0:^;[/]D7]GS3M2GU>P^'MA9:C=37%Q<W5M>ZG"\\MT\DDS2A+P
M*X9YI'"LI568E0#117C9MP[P_GT\)//,CRC.)X"52>!GFF6X/,)8.=;V?M9X
M5XJC5>'E5]C2]I*ER.:IP4FU%6Z:&-QF%C5AAL5B</"NHJO"A7JTH5E&_*JT
M:<HQJJ-W934DKNV[(M;_`&;?!VJ)<6^C:1H6A6RAD@N+JVU75[RX;9%\\B_V
MMIJV:++YJ)Y,DTK1HDGF+O,:<G\//V2O#/@KQ59Z];6'A;0K&UFL;Z^L/"=A
MJUM<^)]0TB_74]#_`+>O=7U74BNF:9J20ZN=/LHXY+W5+2QDN;TVEO-9W917
MBU/#_@[$9CA,YJ\/97+,L*^>CBE@\-&<4Z-2C[*/+27LZ/LJLZ<J=+V<:M.4
MJ==5:<YQEU0S?,J$*]"EC<1"C6BJ56FJCY*D(.K95%M4:=6;3J<SA+DE#E=.
MFX_8E%%%?9GF&-X@\/:'XKT>]\/^)-*L=;T344BCO]+U*!+JRNTAGBN8EG@D
M!218[B"&90P($D:-U`KD/"_P>^%G@G4'U7PE\/\`PGX>U.2![9K_`$O1;*UN
M_(DR)(EN$B$B)("5<(R[U)5LJ<445Y.)R#(L9F>$SK&9+E.*SC`4W2P.;8G+
ML'7S+!4FZC=/"8ZK1EBL/"]:L^2C5A&]6J[?O)WVAB,1"E.A"O6A1J-NI1A5
MG&E-M)-SIJ2A)M))N2>B2Z(MR?"[X=2^"Q\.I/!?AQ_`JQ/"GA5M+M6T6*-Y
M7G80V)C,4+>=+)*)(PLB2.SHRL<U:\$_#OP-\-],?1O`?A30_">F2R^?-::)
MI\%C'/-SB2<Q('G=0S!&E=RBDJN`2***=#(<CPV(P>+PV395A\7E^"CEN`Q5
M#+L'2Q&!RZ"488#!UJ=&-3#8*,4HQPM&4*$4DE321<L9BY4:F'EBL3*A5J^W
MJT)5ZKHU*V_MJE-RY)U;Z^TE%S\RU:>"?"-CIFO:-9^'=*M]*\47>J7WB+3X
MK2-;76;S6PPU>YU"+&VYFU$,PNWD!,P)WYS7%:5\`?@IH>IZ?K.C_"_P7IFK
M:5>6]_INHV6AV=O=V-[:R++;W-M/'&KQ30R*K(ZD$$>A(HHKDQ?"?"V85<#6
MQ_#608VME=O[,JXO)\NQ-3+K5EB%]1G6PTY82U>,:R^KNG:JE4^-7%#%XJG&
MI&GB<1"-56JQA6J1C47+RVJ*,DIKE]WWK^[IL7=<^"7PC\2^*K?QQK_PY\(Z
MMXMM3"T.O7VBV<^H![<_N)))7C(GDB&%22=9'5510V$0+VNF^&O#^CZGK>LZ
M7H^GV&K>))K.XU_4+6VCANM7GL+865E+?S(`UP]K:*MO`7)\N(!%P***ZZ&1
M9)A<34QF&R?*L/BZV+ECZN*H9?A*.)JX^="MA9XVI7IT8U9XN6&Q&(P\L3*3
MK2H5ZU%S=.K.,BIB\75ITZ57%8BI2I4E1I4ZE:I.G3HJ:FJ-.$I.,*2G&,U3
MBE!3BI6NDS$TGX:^`-!?0I-&\(Z#I<GABZUF]\/M9:?#;G1[OQ$LZ:[<6'EJ
MOD2ZLMS<"^9>;CS7,F2<UMIX9\/1^()_%<>BZ:GB6ZTR/1KG7$M(5U.XTJ&8
MW$5A/=JHEEM8YF,B12,RJW3``%%%5ALER?!TJ-#"93EF%HX>O1Q-"EA\!A:%
M.CB<-A*>7X?$4H4Z48TZ]#`4J6"HU8)5*6$I4\-"4:,(P42KUIN4IUJLI2BX
MR<JDY.493=249-MMQE4;FT[IS;DUS.YQ.C_!'X0^'_%,_C71?AQX0TSQ7<S-
M<2Z[9Z)90W_GN\KO/%*L6()F>:5C)"L;Y=L,`<5'K_P,^#WBG5[[7_$?PV\(
M:WK6I2)+?ZIJ6BVEU>W<D<,=O&\\\J,\A2"&*)=Q^6.-%&`H%%%>?B.#^$L9
M@7EF+X7X=Q66RQ\LUEE^(R3+*V"EFDX5*4\REA*F&E0>/G2JU:<\8Z?UB5.I
M4A*HXSDGL\?CW459XW%NLJ4:"JO$UO:*A"W)14^?F5*'+'EII\D;*R5D.\3?
M`_X0^,M,T/1O%/PZ\)ZYIGAJ**#0+2_TBVFCTFW@C:*&VLF*B2&VCC=E2W#^
M2N<A,@$=S)X9\.RZ"_A>30])?PV]F=.?03I]K_9#6)78;0Z?Y7V7R"O'E^5M
M[XSS117?ALCR7!5<17P>497A:^+P]'"8NMAL!A*%;%87#4_98?#8BI2I1G7P
M]"D_9T:-64J=*G[D(QCH1+%XJ<*5*>)Q$Z="<ZE"G*M4E"C4J24JDZ4')QIS
MG)*4Y02E*23DVTCDO`WP?^%WPSGU&Z\`^`_#/A.ZU9P^HW.C:7;VEQ=%2S!9
M)U4RB,,S-Y2.L9)!*D@$<W\4O@3X/^)_A/QGX5E3_A&Q\0[_`,,W?C36-&L[
M(ZIK]OX:U*PO;>UO)KJ&53(UM8BRM;T+]HT[='<6QW0A'**XZ_"G#.(R>IP_
M/(<JADE2ACL,\LP^!H83"0HYEA<3@LPC0I86%%89XS"8W&8;$5,/[*I5HXK$
M4Y3<:U12UAF./AC(9@L9B)8VG4HU8XJI5G5K>TP\Z=2A*4ZKFY^RJ4J4X*?,
MHRIP:7NJWH]SX/\`#-ZGAI=0T:QU!O!UQ;WGAJ:^@2XGT>^MK&33HKZRE<;H
M+L64TUN9TVN8Y9%Z.12Z;X/\*Z1HMYX<TSP_I-GH&HS:G/?:/#90C3KN769I
M;C57N+1E:&4ZA//-+=AT*S/+(S@ECDHKT(Y3E<*TL3'+<`L3.E.A/$?5*'UB
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%USF/_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
